CXCL12 and neoplasm: Activation of the CXCR4/CXCL12 pathway is associated with the formation of an immunosuppressive tumor microenvironment (171), and X4P-001 (a CXCR4 antagonist) can block excessive activation of this pathway to reverse tumor immune escape (172).